← Leaderboards
Kexin Xu
Dana-Farber Cancer Inst
$3,572,606
Attributed
$3,572,606
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,572,606 · 5
By mechanism
R01$2,546,910 · 2
R00$498,001 · 1
R21$401,947 · 1
K99$125,748 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Steven P. Balk$19,509,335
- Jeffrey Wade Harper$36,219,392
- Mark M. Pomerantz$1,781,713
- Sabina Signoretti$9,867,905
- Matthew L Freedman$13,331,420
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesComplexProteinsMutantMethyltransferaseProteomicsTranscriptome SequencingBiologicalBindingMethylationSignal TransductionLinkPathway InteractionsReportingDrug TargetingMediatingTumor ProgressionOncogenicMolecularEpigenetic ProcessCell PhysiologyBaseMutationMutate
Grant awards (14)
Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.$412,955
R01 · FY2025 · CA · contact PI
METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs$347,225
R01 · FY2025 · GM · contact PI
Development of a new class of EZH2 inhibitors in ERa-negative breast cancer$188,753
R21 · FY2025 · CA · contact PI
Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.$439,997
R01 · FY2024 · CA · contact PI
METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs$347,225
R01 · FY2024 · GM · contact PI
Development of a new class of EZH2 inhibitors in ERa-negative breast cancer$126,477
R21 · FY2024 · CA · contact PI
Development of a new class of EZH2 inhibitors in ERa-negative breast cancer.$86,717
R21 · FY2024 · CA · contact PI
METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs$333,187
R01 · FY2023 · GM · contact PI
METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs$333,250
R01 · FY2022 · GM · contact PI
METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs$333,071
R01 · FY2021 · GM · contact PI
Polycomb -Independent Functions of EZH2 in Castration Resistant Prostate Cancer$1
R00 · FY2017 · CA · contact PI
Polycomb -Independent Functions of EZH2 in Castration Resistant Prostate Cancer$249,000
R00 · FY2016 · CA · contact PI
Polycomb -Independent Functions of EZH2 in Castration Resistant Prostate Cancer$249,000
R00 · FY2015 · CA · contact PI
Polycomb -Independent Functions of EZH2 in Castration Resistant Prostate Cancer$125,748
K99 · FY2014 · CA · contact PI